And, recently, two cancer drug trials were paused after evidences of bleeding disorders in patients receiving anti-PDL-1 therapy (Kestrell Study -https://uk.reuters.com/article/us-astrazeneca-cancer/astrazeneca-pauses-two-cancer-drug-trials-enrolment-due-to-bleeding-idUKKCN12R2D4). Here, CD274 is linked to hemorrhagic disease.